Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Februar 2026 08:00 ET | Quelle: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer

Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary; Bryan Jones Named Chief Executive Officer
12. Februar 2026 08:00 ET | Quelle: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces Leadership Appointments

Aardvark Therapeutics Announces Leadership Appointments
10. Februar 2026 08:00 ET | Quelle: Aardvark Therapeutics, Inc.

Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome

Aardvark Therapeutics announced a Phase 3 HERO trial protocol amendment expanding eligibility for patients with Prader-Willi Syndrome.